Work

A phase 1b study of the OxPhos inhibitor ME-344 in combination with bevacizumab in refractory metastatic colorectal cancer.

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.3_suppl.tps222

Authors: Patrick M Boland, Heinz-Josef Lenz, Mike Cusnir, Vaia Florou, Michael J. Pishvaian, Deirdre J. Cohen, Kristen Keon Ciombor, Arthur Winer, Jessie Yanxiang Guo, Sandra Algaze, Sandra E Wiley, Richard Ghalie, Howard S. Hochster

Institutions: Rutgers Cancer Institute, University of Southern California, USC Norris Comprehensive Cancer Center, Mount Sinai Medical Center, Huntsman Cancer Institute, Johns Hopkins University, Icahn School of Medicine at Mount Sinai, Vanderbilt University Medical Center, Inova Fairfax Hospital, MEI Pharma (United States)

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4391096742

Cites:

Cited by:

Related to: 10